Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Pharma Mar SA ( (ES:PHM) ).
Pharma Mar SA has concluded its share buy-back program ahead of schedule, having reached the maximum monetary amount of €5,000,000. The program, which resulted in the acquisition of 58,870 shares, representing 0.32% of the company’s share capital, was aimed at fulfilling obligations under the company’s Share Plans for executives and employees. Following the conclusion of the buy-back program, the company will resume operations under its liquidity contract with JB Capital Markets, effective February 25, 2025.
More about Pharma Mar SA
Pharma Mar SA operates in the pharmaceutical industry, focusing on the development and commercialization of marine-derived drugs for oncology treatment. The company is known for its innovative approach in leveraging marine biodiversity to create novel therapies for cancer patients.
YTD Price Performance: 26.28%
Average Trading Volume: 1,486
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.86B
Learn more about PHM stock on TipRanks’ Stock Analysis page.